Briefcase Email Alerts Downloads Snapshot RSS Email Printed Materials Print this page

Achieve

Press Releases


 
Press Releases
  Date Title and Summary View
Aug 11, 2009
Cambridge, Mass. and Carlsbad, Calif. – August 11, 2009 – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, and Regulus Therapeutics Inc., a leading microRNA therapeutics company, announced today that the United States Patent and Trademark Office (USPTO) has awarded a notice of allowance...
Jul 7, 2009
CAMBRIDGE, Mass. and CARLSBAD, Calif., September 7, 2007 – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announced today the launch of Regulus Therapeutics LLC, a joint venture focused on the discovery, development, and commercialization of microRNA (miRNA) therapeutics. Because miRNAs regulate ...
May 14, 2009
CARLSBAD, Calif., May 14, 2009 – Regulus Therapeutics Inc. today announced that it achieved the initial milestone with GlaxoSmithKline (GSK) as part of their ongoing worldwide strategic alliance established to discover, develop and market novel microRNA-based therapeutics to treat inflammatory diseases. The two companies are ...
Mar 4, 2009
CARLSBAD, Calif., and CAMBRIDGE, Mass., March 4, 2009 – Regulus Therapeutics Inc., Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY) and Isis Pharmaceuticals, Inc. (Nasdaq:ISIS) announced today that Regulus has raised $20 million in a Series A preferred equity financing that further strengthens its balance sheet. Alnylam and Isis w...
Nov 30, 2008
CAMBRIDGE, Mass. & CARLSBAD, Calif.–(BUSINESS WIRE)– Regulus Therapeutics LLC, a joint venture between Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) formed to discover, develop, and commercialize microRNA-based therapeutics, announced today the publication of new research in the journal&n...
Nov 6, 2008
CAMBRIDGE, Mass. & CARLSBAD, Calif.–(BUSINESS WIRE)– Regulus Therapeutics LLC, a joint venture between Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) formed to discover, develop, and commercialize microRNA-based therapeutics, announced today the publication of new research findings in the ...
Sep 4, 2008
CAMBRIDGE, Mass. and CARLSBAD, Calif., September 4, 2008 – Isis Pharmaceuticals, Inc. (Nasdaq: ISIS), Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), and the companies’ joint venture Regulus Therapeutics LLC, announced today that the United States Patent and Trademark Office (USPTO) has granted notices of...
Sep 3, 2008
CAMBRIDGE, Mass. and CARLSBAD, Calif., September 3, 2008 – Regulus Therapeutics LLC, a joint venture between Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) formed to discover, develop, and commercialize microRNA-based therapeutics, announced today the appointment of Stelios Papadopo...
Aug 19, 2008
CAMBRIDGE, Mass. and CARLSBAD, Calif., August 19, 2008 – Regulus Therapeutics LLC, a joint venture between Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) formed to discover, develop, and commercialize microRNA-based therapeutics, announced today the publication of new research in th...
Aug 4, 2008
CAMBRIDGE, Mass. and CARLSBAD, Calif., August 4, 2008 – Regulus Therapeutics LLC, a joint venture between Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) formed to discover, develop, and commercialize microRNA-based therapeutics, announced today the appointment of Garry Menzel, Ph.D....
Page: FirstPrevious ...
20
NextLast
= add release to Briefcase